Table 8.
Values of physical examination, diagnostic imaging, and laboratory variables for those dogs that developed congestive heart failure, measured at the time of onset of heart failure summarized for the 2 treatment groups
| Continuous Variables | Treatment Group | N | Median Value at CHF and IQR | Between‐Group Comparison | |
|---|---|---|---|---|---|
| Physical examination variables | Body weight (kg) | Placebo | 73 | 8.7 (6.9–10.6) | 0.96 |
| Pimobendan | 58 | 9.2 (7.1–10.0) | |||
| Rectal temperature (°C) | Placebo | 66 | 38.6 (38.3–38.8) | 0.11 | |
| Pimobendan | 56 | 38.4 (38.0–38.8) | |||
| Respiratory rate (breaths/min) | Placebo | 69 | 44 (40–58) | 0.25 | |
| Pimobendan | 52 | 50 (36–66) | |||
| Owner‐measured resting respiratory rate (breaths/min) | Placebo | 58 | 36 (30–50) | 0.50 | |
| Pimobendan | 50 | 39 (34–50) | |||
| Heart rate (BPM) | Placebo | 71 | 150 (140–162) | 0.60 | |
| Pimobendan | 58 | 150 (140–164) | |||
| Diagnostic imaging variables | FS% (%) | Placebo | 67 | 46.6 (42.5–50.1) | 0.63 |
| Pimobendan | 55 | 46 (42.0–53.8) | |||
| LVIDDN | Placebo | 67 | 2.26 (2.14–2.51) | 0.94 | |
| Pimobendan | 55 | 2.27 (2.14–2.47) | |||
| LA/Ao | Placebo | 67 | 2.41 (2.15–2.80) | 1.00 | |
| Pimobendan | 55 | 2.47 (2.17–2.71) | |||
| LVIDSN | Placebo | 67 | 1.16 (1.03–1.33) | 0.62 | |
| Pimobendan | 55 | 1.13 (0.98–1.36) | |||
| VHS | Placebo | 72 | 13.0 (12.2–13.5) | 0.45 | |
| Pimobendan | 59 | 12.8 (12.1–13.5) | |||
| Laboratory variables | Na+ (mmol/L) | Placebo | 68 | 147.0 (145.4–150.0) | 0.66 |
| Pimobendan | 55 | 147.0 (146.0–149.0) | |||
| K+ (mmol/L) | Placebo | 68 | 4.50 (4.25–4.80) | 0.40 | |
| Pimobendan | 52 | 4.50 (4.00–4.80) | |||
| PCV (%) | Placebo | 66 | 41.5 (37.4–48.0) | 0.12 | |
| Pimobendan | 50 | 44.0 (40.0–47.0) | |||
| Creatinine (μmol/L) | Placebo | 68 | 78.8 (61.9–90.0) | 0.90 | |
| Pimobendan | 52 | 79.6 (64.9–87.2) | |||
| TPC (g/L) | Placebo | 66 | 64.0 (58.0–70.0) | 0.77 | |
| Pimobendan | 52 | 66.0 (60.5–68.0) | |||
| GPT (ALT) (U/L) | Placebo | 62 | 52.5 (35.0–77.0) | 0.68 | |
| Pimobendan | 51 | 54.0 (34.0–95.0) |
ALT, alanine aminotransferase; BPM, beats per minute; FS%, fractional shortening; GPT, glutamic‐pyruvate transaminase; K+, potassium concentration; LA/Ao, left atrial‐to‐aortic root ratio; LVIDDN, normalized left ventricular internal diameter in diastole; LVIDSN, normalized left ventricular internal diameter in systole; Na+, sodium concentration; PCV, packed cell volume; TPC, total protein concentration; VHS, vertebral heart sum.